ER、PR、HER-2阴性乳腺癌研究进展

Research progress in triple-negative breast cancer

ER、PR、HER-2均为阴性的乳腺癌（三阴乳腺癌）常较早发生远处转移，内脏转移率高于骨转移，预后较差。由于没有内分泌和靶向HER-2治疗的机会，因此只能将化疗作为主要的治疗手段。其主要增殖信号和分子学特征提示针对表皮生长因子受体（EGFR）、C—kit和BRCA1等靶点的靶向治疗可能发挥较好的治疗效果。但目前的研究结果还不能明确三阴乳腺癌的生物学特点和最佳治疗策略。

＂Triple-negative＂ breast cancer patients who have special clinicopathological characteristics are defined by a lack expression of oestrogen,progesterone,and HER-2 receptors. Triple- negative patients usually metastasize early with worse prognosis ,and have a higher incidence of visceral metastases than bony metastases. This subgroup has no chance of hormone treatment and targeted therapy for HER-2 ,and chemotherapy is the main therapy. We discuss the predominant proliferative signals, molecular features of triple- negative breast cancer,and some basic studies and clinical trials. Furthermore, targeted therapy against EGFR, C-kit, and BRCAI may show preferable anticancer activity. However, recent research is still unable to identify the biological characteristics of triple-negative cancer, and special treatment is still not available.